Voyager Therapeutics Company Profile (NASDAQ:VYGR)

About Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics logoVoyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VYGR
  • CUSIP: N/A
  • Web: www.voyagertherapeutics.com
Capitalization:
  • Market Cap: $494.21 million
  • Outstanding Shares: 26,903,000
Average Prices:
  • 50 Day Moving Avg: $10.74
  • 200 Day Moving Avg: $10.41
  • 52 Week Range: $8.10 - $19.67
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.09
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $8.31 million
  • Price / Sales: 59.47
  • Book Value: $4.05 per share
  • Price / Book: 4.54
Profitability:
  • EBIDTA: ($59,320,000.00)
  • Net Margins: -712.22%
  • Return on Equity: -46.15%
  • Return on Assets: -32.66%
Debt:
  • Current Ratio: 12.23%
  • Quick Ratio: 12.23%
Misc:
  • Average Volume: 206,402 shs.
  • Beta: 3.65
  • Short Ratio: 6.77
 

Frequently Asked Questions for Voyager Therapeutics (NASDAQ:VYGR)

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.11. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. View Voyager Therapeutics' Earnings History.

Where is Voyager Therapeutics' stock going? Where will Voyager Therapeutics' stock price be in 2017?

8 brokerages have issued twelve-month price targets for Voyager Therapeutics' stock. Their forecasts range from $12.00 to $37.00. On average, they expect Voyager Therapeutics' stock price to reach $24.83 in the next year. View Analyst Ratings for Voyager Therapeutics.

What are analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:

  • 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/11/2017)
  • 2. Cowen and Company analysts commented, "VYGR had a 6/30 cash balance of $141MM, sufficient to fund operations into 2019." (8/8/2017)
  • 3. Instinet analysts commented, "We are initiating on Voyager Therapeutics (VYGR) with a Buy rating and $31 target price. We anticipate updates from the ongoing trial of VY-AADC01 confirming efficacy, safety, and framing durability/duration of effect to drive upside in the share price over the next 12 months. In addition, we believe that data and initiation of a pivotal trial in advanced Parkinson's will attract investor attention, as the direct-to-CNS delivery of an enzyme becomes increasingly viewed as a risk-reduced approach to gene therapy with a rapidly addressable $1.5bn DBS-like market opportunity in advanced PD." (3/1/2017)

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a decrease in short interest during the month of August. As of August 15th, there was short interest totalling 469,003 shares, a decrease of 41.6% from the July 31st total of 803,724 shares. Based on an average daily volume of 125,749 shares, the days-to-cover ratio is presently 3.7 days. Approximately 3.0% of the shares of the company are sold short.

Who are some of Voyager Therapeutics' key competitors?

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:

  • Mark J. Levin, Independent Chairman of the Board
  • Steven M. Paul M.D., President, Chief Executive Officer, Director
  • Jane Pritchett Henderson, Chief Financial Officer, Senior Vice President
  • Robert G. Pietrusko, Senior Vice President - Regulatory Affairs
  • Dinah Sah Ph.D., Chief Scientific Officer
  • Kathleen Hayes, Vice President - Human Resources
  • John J. Connelly, Vice President - Program and Alliance Management
  • Bernard Ravina M.D., Chief Medical Officer
  • Glenn F. Pierce M.D., Ph.D., Director
  • Wendy L. Dixon Ph.D., Independent Director

Who owns Voyager Therapeutics stock?

Voyager Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.01%), Bain Capital Public Equity Management LLC (4.37%), Vanguard Group Inc. (1.60%), DAFNA Capital Management LLC (0.76%), State Street Corp (0.69%) and Northern Trust Corp (0.50%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina and Steven M Paul. View Institutional Ownership Trends for Voyager Therapeutics.

Who sold Voyager Therapeutics stock? Who is selling Voyager Therapeutics stock?

Voyager Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management LLC and New York State Common Retirement Fund. View Insider Buying and Selling for Voyager Therapeutics.

Who bought Voyager Therapeutics stock? Who is buying Voyager Therapeutics stock?

Voyager Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Dimensional Fund Advisors LP, HarbourVest Partners LLC, Northern Trust Corp, Bessemer Group Inc., State Street Corp, Oppenheimer & Co. Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Voyager Therapeutics.

How do I buy Voyager Therapeutics stock?

Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of Voyager Therapeutics stock can currently be purchased for approximately $18.37.


MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  225
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Voyager Therapeutics (NASDAQ:VYGR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $24.83 (35.18% upside)

Analysts' Ratings History for Voyager Therapeutics (NASDAQ:VYGR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/10/2017Chardan CapitalReiterated RatingHoldMediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$12.00HighView Rating Details
8/8/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
7/28/2017Stifel NicolausInitiated CoverageBuy$20.00HighView Rating Details
5/10/2017WedbushReiterated RatingOutperform$36.00MediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$31.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$37.00N/AView Rating Details
5/20/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Voyager Therapeutics (NASDAQ:VYGR)
Earnings by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Earnings History by Quarter for Voyager Therapeutics (NASDAQ VYGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.62)($0.73)$3.27 million$1.18 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.54)($0.65)$3.70 million$1.46 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.46)($0.57)$4.15 million$2.36 millionViewN/AView Earnings Details
8/11/2016Q2($0.34)($0.37)$4.79 million$3.72 millionViewListenView Earnings Details
5/12/2016Q1($0.38)$0.29$5.00 million$4.83 millionViewListenView Earnings Details
3/17/2016Q4($0.55)($0.67)$5.00 million$4.94 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Voyager Therapeutics (NASDAQ:VYGR)
2017 EPS Consensus Estimate: ($2.69)
2018 EPS Consensus Estimate: ($2.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.78)($0.78)($0.78)
Q4 20171($0.85)($0.85)($0.85)
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.73)($0.73)($0.73)
Q3 20181($0.62)($0.62)($0.62)
Q4 20181($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Voyager Therapeutics (NASDAQ:VYGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Voyager Therapeutics (NASDAQ:VYGR)
Insider Ownership Percentage: 6.00%
Institutional Ownership Percentage: 40.70%
Insider Trades by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Insider Trades by Quarter for Voyager Therapeutics (NASDAQ:VYGR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/11/2017Bernard RavinaInsiderSell16,470$12.87$211,968.90View SEC Filing  
9/5/2017Bernard RavinaInsiderSell5,490$10.00$54,900.00View SEC Filing  
7/20/2017Bernard RavinaInsiderSell5,490$10.00$54,900.00View SEC Filing  
1/14/2016Steven M PaulCEOBuy10,000$14.07$140,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Voyager Therapeutics (NASDAQ:VYGR)
Latest Headlines for Voyager Therapeutics (NASDAQ:VYGR)
Source:
DateHeadline
americanbankingnews.com logoContrasting Voyager Therapeutics (VYGR) & GTx (GTXI)
www.americanbankingnews.com - September 20 at 6:10 PM
finance.yahoo.com logoVoyager Therapeutics Appoints Matthew P. Ottmer as Chief Operating Officer
finance.yahoo.com - September 19 at 9:29 AM
americanbankingnews.com logo$1.15 Million in Sales Expected for Voyager Therapeutics, Inc. (VYGR) This Quarter
www.americanbankingnews.com - September 18 at 5:14 PM
finance.yahoo.com logo3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
finance.yahoo.com - September 17 at 9:19 AM
americanbankingnews.com logoInsider Selling: Voyager Therapeutics, Inc. (VYGR) Insider Sells 5,490 Shares of Stock
www.americanbankingnews.com - September 13 at 8:50 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Insider Bernard Ravina Sells 16,470 Shares
www.americanbankingnews.com - September 13 at 8:28 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Earns "Hold" Rating from Chardan Capital
www.americanbankingnews.com - September 11 at 8:58 PM
americanbankingnews.com logoCritical Comparison: Voyager Therapeutics (VYGR) versus Merrimack Pharmaceuticals (MACK)
www.americanbankingnews.com - September 8 at 10:30 AM
finance.yahoo.com logoHere's Why Voyager Therapeutics Gained as Much as 24.9% Today
finance.yahoo.com - September 7 at 11:04 AM
americanbankingnews.com logoNovavax (NVAX) versus Voyager Therapeutics (VYGR) Head-To-Head Review
www.americanbankingnews.com - September 6 at 8:26 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 6 at 4:50 PM
finance.yahoo.com logoVoyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
finance.yahoo.com - September 6 at 10:08 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - September 2 at 12:06 AM
feeds.benzinga.com logoVoyager Therapeutics to Participate in September Investor Conferences
feeds.benzinga.com - August 30 at 2:20 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Expected to Announce Quarterly Sales of $1.15 Million
www.americanbankingnews.com - August 30 at 9:12 AM
americanbankingnews.com logo Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) to Post -$0.69 Earnings Per Share
www.americanbankingnews.com - August 28 at 2:22 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Short Interest Down 41.6% in August
www.americanbankingnews.com - August 28 at 1:20 AM
americanbankingnews.com logoVoyager Therapeutics (VYGR) versus Galapagos NV (GLPG) Critical Comparison
www.americanbankingnews.com - August 25 at 12:22 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - August 16 at 5:40 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 12 at 5:02 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - August 11 at 4:00 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Voyager Therapeutics, Inc. Decreased by Wedbush (VYGR)
www.americanbankingnews.com - August 11 at 7:48 AM
finance.yahoo.com logoEdited Transcript of VYGR earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 9:34 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (NASDAQ:VYGR) Announces Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - August 9 at 2:34 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (NASDAQ:VYGR) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - August 9 at 12:38 AM
finance.yahoo.com logoVoyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights
finance.yahoo.com - August 8 at 8:15 AM
finance.yahoo.com logoVoyager Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 8:15 AM
feeds.benzinga.com logoVoyager Therapeutics to Host Second Quarter 2017 Financial Results and Corporate Highlights Conference Call
feeds.benzinga.com - August 2 at 12:38 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (NASDAQ:VYGR) to Release Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:22 AM
americanbankingnews.com logoComparing Voyager Therapeutics (VYGR) & Codexis (CDXS)
www.americanbankingnews.com - July 30 at 6:24 PM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Research Coverage Started at Stifel Nicolaus
www.americanbankingnews.com - July 28 at 9:06 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 18 at 5:03 PM
nasdaq.com logoVoyager Therapeutics Announces Publication from the California Institute of Technology of a Second-
www.nasdaq.com - July 17 at 11:30 AM
finance.yahoo.com logoVoyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain
finance.yahoo.com - July 17 at 11:30 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - July 13 at 10:20 PM
americanbankingnews.com logoZacks Investment Research Lowers Voyager Therapeutics, Inc. (NASDAQ:VYGR) to Sell
www.americanbankingnews.com - July 13 at 10:23 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) Will Announce Quarterly Sales of $3.24 Million
www.americanbankingnews.com - June 28 at 9:51 AM
americanbankingnews.com logo-$0.63 EPS Expected for Voyager Therapeutics, Inc. (VYGR) This Quarter
www.americanbankingnews.com - June 26 at 8:38 PM
streetinsider.com logoVoyager Therapeutics (VYGR) Reports Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
www.streetinsider.com - June 26 at 9:31 AM
finance.yahoo.com logoVoyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
finance.yahoo.com - June 26 at 9:31 AM
americanbankingnews.com logoVoyager Therapeutics, Inc. (VYGR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 23 at 2:50 PM
finance.yahoo.com logoETFs with exposure to Voyager Therapeutics, Inc. : June 19, 2017
finance.yahoo.com - June 20 at 9:13 AM
finance.yahoo.com logoETFs with exposure to Voyager Therapeutics, Inc. : June 5, 2017
finance.yahoo.com - June 6 at 1:53 AM
americanbankingnews.com logo$3.24 Million in Sales Expected for Voyager Therapeutics Inc (VYGR) This Quarter
www.americanbankingnews.com - June 2 at 1:10 PM
finance.yahoo.com logoVoyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
finance.yahoo.com - June 2 at 6:02 AM
americanbankingnews.com logo-$0.63 Earnings Per Share Expected for Voyager Therapeutics Inc (VYGR) This Quarter
www.americanbankingnews.com - May 31 at 4:22 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 2:58 PM
americanbankingnews.com logoVoyager Therapeutics Inc (VYGR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 17 at 9:38 AM
americanbankingnews.com logoWedbush Weighs in on Voyager Therapeutics Inc's Q2 2017 Earnings (VYGR)
www.americanbankingnews.com - May 12 at 7:52 AM
finance.yahoo.com logoEdited Transcript of VYGR earnings conference call or presentation 9-May-17 9:30pm GMT
finance.yahoo.com - May 11 at 3:20 AM

Social

Chart

Voyager Therapeutics (VYGR) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff